Evidence-Based Approach to One Health Vaccinology

Only a few human vaccine trials have been reported from the least developed countries. The target population of biological products often does not have the same opportunity to participate in pre-and post-licensing studies (۱). The COVID-۱۹ vaccine trials may have been exceptional. At the same time, in many developing countries, biopharmaceutical research and development have not been pursued with the same vigor as other pharmaceutical industries. For example, despite a century of history of the vaccine industry in a country like Iran, the allocated budget and established infrastructures in the contemporary have not been parallel to other fields of the pharmaceutical industry. On a global scale, the progress of the animal vaccine industry is not comparable to that of humans. A detailed comparative review of human and animal vaccine research methodology revealed that the concepts are not apparent in the animal sector (۲). Accordingly, the terminology and assessment of animal vaccines should be standardized and strictly applied. A surveillance system that follows up on vaccines and adverse reaction information is an exemplary human benefit. Although, in many cases, there is no such infrastructure in the animal sector, so it is not possible, to a certain extent, to assess the safety and effectiveness information of approved animal vaccines.

کلیدواژه ها:

Pharmaceutical industries ، National immunization program ، Non-specific effects ، vaccine ، Vaccination